49 related articles for article (PubMed ID: 30207027)
21. Rituximab in treatment-resistant autoimmune blistering skin disorders.
Schmidt E; Bröcker EB; Goebeler M
Clin Rev Allergy Immunol; 2008 Feb; 34(1):56-64. PubMed ID: 18270859
[TBL] [Abstract][Full Text] [Related]
22. Practice and Educational Gaps in Blistering Disease.
Ehsani-Chimeh N; Marinkovich MP
Dermatol Clin; 2016 Jul; 34(3):251-6. PubMed ID: 27363880
[TBL] [Abstract][Full Text] [Related]
23. [Rituximab (anti-CD20) for the treatment of autoimmune bullous diseases].
Kasperkiewicz M; Zillikens D
Hautarzt; 2007 Feb; 58(2):115-6, 118-21. PubMed ID: 17237928
[TBL] [Abstract][Full Text] [Related]
24. Rituximab in refractory autoimmune bullous diseases.
Schmidt E; Hunzelmann N; Zillikens D; Bröcker EB; Goebeler M
Clin Exp Dermatol; 2006 Jul; 31(4):503-8. PubMed ID: 16716150
[TBL] [Abstract][Full Text] [Related]
25. B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders.
Stübgen JP
J Neuroimmunol; 2008 Nov; 204(1-2):1-12. PubMed ID: 18783837
[TBL] [Abstract][Full Text] [Related]
26. The therapeutic potential of anti-CD20 "what do B-cells do?".
Eisenberg R; Looney RJ
Clin Immunol; 2005 Dec; 117(3):207-13. PubMed ID: 16169773
[TBL] [Abstract][Full Text] [Related]
27. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases.
Hertl M; Zillikens D; Borradori L; Bruckner-Tuderman L; Burckhard H; Eming R; Engert A; Goebeler M; Hofmann S; Hunzelmann N; Karlhofer F; Kautz O; Lippert U; Niedermeier A; Nitschke M; Pfütze M; Reiser M; Rose C; Schmidt E; Shimanovich I; Sticherling M; Wolff-Franke S
J Dtsch Dermatol Ges; 2008 May; 6(5):366-73. PubMed ID: 18201220
[TBL] [Abstract][Full Text] [Related]
28. [Rituximab: a original biotherapy in auto-immune disorders].
Sibilia J; Sordet C
Rev Med Interne; 2005 Jun; 26(6):485-500. PubMed ID: 15936477
[TBL] [Abstract][Full Text] [Related]
29. B cell-targeted immunotherapy for type 1 diabetes: What can make it work?
Hamad AR; Ahmed R; Donner T; Fousteri G
Discov Med; 2016 Mar; 21(115):213-9. PubMed ID: 27115172
[TBL] [Abstract][Full Text] [Related]
30. [Rationale and clinical evidence for the use of rituximab in glomerular diseases].
Mani LY; Vogt B; Burnier M; Golshayan D
Rev Med Suisse; 2011 Apr; 7(290):819-24. PubMed ID: 21595313
[TBL] [Abstract][Full Text] [Related]
31. Emerging approaches for the therapy of autoimmune and chronic inflammatory disease.
Cope AP; Feldmann M
Curr Opin Immunol; 2004 Dec; 16(6):780-6. PubMed ID: 15511673
[TBL] [Abstract][Full Text] [Related]
32. [Acquired autoimmune haemophilia: Where is the place of rituximab in the treatment strategy? Reflection from a monocentric series of 8 patients and literature review].
Grossin D; Broner J; Arnaud E; Goulabchand R; Gris JC
Rev Med Interne; 2019 Sep; 40(9):574-580. PubMed ID: 30904179
[TBL] [Abstract][Full Text] [Related]
33. Autoimmune Sequelae Following Rituximab Therapy: A Review of the Literature and Potential Immunologic Mechanisms.
Kersh AE; Feldman RJ
J Clin Rheumatol; 2018 Dec; 24(8):427-435. PubMed ID: 29561469
[TBL] [Abstract][Full Text] [Related]
34. CD20-depleting therapy in autoimmune diseases: from basic research to the clinic.
Perosa F; Prete M; Racanelli V; Dammacco F
J Intern Med; 2010 Mar; 267(3):260-77. PubMed ID: 20201920
[TBL] [Abstract][Full Text] [Related]
35. The clinical efficacy of Rituximab administration in autoimmunity disorders, primary immunodeficiency diseases and malignancies.
Zian Z; Berry SPD; Bahmaie N; Ghotbi D; Kashif A; Madkaikar M; Bargir UA; Abdullahi H; Khan H; Azizi G
Int Immunopharmacol; 2021 Jun; 95():107565. PubMed ID: 33773205
[TBL] [Abstract][Full Text] [Related]
36. Rituximab: a B-cell depletion therapy for dermatologic disease.
Prajapati V; Mydlarski PR
Skin Therapy Lett; 2007; 12(6):6-9. PubMed ID: 17762903
[TBL] [Abstract][Full Text] [Related]
37. B-cell-directed therapy for inflammatory skin diseases.
Nagel A; Hertl M; Eming R
J Invest Dermatol; 2009 Feb; 129(2):289-301. PubMed ID: 19148218
[TBL] [Abstract][Full Text] [Related]
38. Rituximab therapy for autoimmune haematological diseases.
Barcellini W; Zanella A
Eur J Intern Med; 2011 Jun; 22(3):220-9. PubMed ID: 21570637
[TBL] [Abstract][Full Text] [Related]
39. Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris.
El Tal AK; Posner MR; Spigelman Z; Ahmed AR
J Am Acad Dermatol; 2006 Sep; 55(3):449-59. PubMed ID: 16908351
[TBL] [Abstract][Full Text] [Related]
40. Preliminary analysis of mortality associated with rituximab use in autoimmune diseases.
Shetty S; Ahmed AR
Autoimmunity; 2013 Dec; 46(8):487-96. PubMed ID: 24151854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
